DDInter1042 DDInter1909
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.
Valbenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Valbenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Valbenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Valbenazine {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Valbenazine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Valbenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin
Valbenazine may lead to a major life threatening interaction when taken with Enzalutamide
Valbenazine may lead to a major life threatening interaction when taken with Dacomitinib